Research programme: bladder cancer therapeutics - SerometrixAlternative Names: SX-MTR1
Latest Information Update: 12 Jul 2016
At a glance
- Originator Serometrix
- Class Antineoplastics
- Mechanism of Action MTOR protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Bladder cancer
Most Recent Events
- 12 Jul 2016 Early research in Bladder cancer in USA (unspecified route)